Exact Sciences Posts Flat Q2 Revenues | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exact Sciences today reported flat year-over-year second-quarter revenues and a slight increase in its net loss, as the firm continues studies of its stool-based DNA test for colorectal cancer.

The Madison, Wis.-based molecular diagnostics firm brought in a total of $1.3 million in revenues for the three-month period ended June 30, roughly flat with the second quarter of 2009. Almost the entirety of revenues came from license fees.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.